Cutaneous T-cell lymphoma: 2014 update on diagnosis, risk-stratification, and management (Q27024076)

language of work or name

1 reference

August 2014

1 reference

American Journal of Hematology

published in

1 reference

volume

89

1 reference

issue

8

1 reference

page(s)

837-51

1 reference

WHO-EORTC classification for cutaneous lymphomas

cites work

1 reference

Incidence of cutaneous T-cell lymphoma in the United States, 1973-2002.

21 January 2018

1 reference

Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases

21 January 2018

1 reference

Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal.

21 January 2018

1 reference

Mycosis fungoides in relation to environmental exposures and immune response: a case-control study

21 January 2018

1 reference

Hydrochlorothiazide and cutaneous T cell lymphoma: prospective analysis and case series

21 January 2018

1 reference

Familial mycosis fungoides: report of 6 kindreds and a study of the HLA system.

21 January 2018

1 reference

The vast majority of CLA+ T cells are resident in normal skin.

21 January 2018

1 reference

CC chemokine receptor (CCR)4 and the CCR10 ligand cutaneous T cell-attracting chemokine (CTACK) in lymphocyte trafficking to inflamed skin

21 January 2018

1 reference

CCL27-CCR10 interactions regulate T cell-mediated skin inflammation

21 January 2018

1 reference

Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors

21 January 2018

1 reference

Genome-wide analysis of cutaneous T-cell lymphomas identifies three clinically relevant classes.

21 January 2018

1 reference

Oncogenomic analysis of mycosis fungoides reveals major differences with Sezary syndrome.

21 January 2018

1 reference

Regulatory T cells and immunodeficiency in mycosis fungoides and Sézary syndrome.

21 January 2018

1 reference

Monocytes promote tumor cell survival in T-cell lymphoproliferative disorders and are impaired in their ability to differentiate into mature dendritic cells.

21 January 2018

1 reference

Skin-resident T cells: the ups and downs of on site immunity

21 January 2018

1 reference

Aberrant Cytokine Production By Sezary Syndrome Patients: Cytokine Secretion Pattern Resembles Murine Th2 Cells

21 January 2018

1 reference

Classification and prediction of survival in patients with the leukemic phase of cutaneous T cell lymphoma

21 January 2018

1 reference

Quantitative PCR on 5 genes reliably identifies CTCL patients with 5% to 99% circulating tumor cells with 90% accuracy

21 January 2018

1 reference

PLCG1 mutations in cutaneous T-cell lymphomas

21 January 2018

1 reference

Gamma c-signaling cytokines induce a regulatory T cell phenotype in malignant CD4+ T lymphocytes.

21 January 2018

1 reference

Interleukin-7 is a growth factor for Sézary lymphoma cells

21 January 2018

1 reference

Skin-derived interleukin-7 contributes to the proliferation of lymphocytes in cutaneous T-cell lymphoma

21 January 2018

1 reference

Prediction of Survival in Follicular Lymphoma Based on Molecular Features of Tumor-Infiltrating Immune Cells

21 January 2018

1 reference

The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma

21 January 2018

1 reference

Tumor-associated macrophages and survival in classic Hodgkin's lymphoma

21 January 2018

1 reference

High numbers of DC-SIGN+ dendritic cells in lesional skin of cutaneous T-cell lymphoma

21 January 2018

1 reference

Cancer-associated myeloproliferation: old association, new therapeutic target

21 January 2018

1 reference

Lesional gene expression profiling in cutaneous T-cell lymphoma reveals natural clusters associated with disease outcome

21 January 2018

1 reference

B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders.

21 January 2018

1 reference

Septicemic complications of the cutaneous T-cell lymphomas

21 January 2018

1 reference

Infections Complicating Mycosis Fungoides and Sézary Syndrome

21 January 2018

1 reference

Circulating natural killer lymphocytes are potential cytotoxic effectors against autologous malignant cells in sezary syndrome patients

21 January 2018

1 reference

Increased programmed death-1 expression on CD4+ T cells in cutaneous T-cell lymphoma: implications for immune suppression

21 January 2018

1 reference

Profound loss of T-cell receptor repertoire complexity in cutaneous T-cell lymphoma

21 January 2018

1 reference

Early lymphocyte recovery predicts superior survival after autologous stem cell transplantation in non-Hodgkin lymphoma: a prospective study

21 January 2018

1 reference

Absolute lymphocyte count at the time of first relapse predicts survival in patients with diffuse large B-cell lymphoma

21 January 2018

1 reference

Lymphopenia assessed during routine follow-up after immunochemotherapy (R-CHOP) is a risk factor for predicting relapse in patients with diffuse large B-cell lymphoma

21 January 2018

1 reference

Absolute lymphocyte count predicts overall survival in follicular lymphomas.

21 January 2018

1 reference

Incidence of TCR and TCL1 gene translocations and isochromosome 7q in peripheral T-cell lymphomas using fluorescence in situ hybridization.

21 January 2018

1 reference

Recurrent translocations involving the IRF4 oncogene locus in peripheral T-cell lymphomas

21 January 2018

1 reference

Specificity of IRF4 translocations for primary cutaneous anaplastic large cell lymphoma: a multicenter study of 204 skin biopsies

21 January 2018

1 reference

Oncogenic activation of NF-kappaB.

21 January 2018

1 reference

Constitutive expression of NF-kappa B is a characteristic feature of mycosis fungoides: implications for apoptosis resistance and pathogenesis

21 January 2018

1 reference

Down-regulating constitutive activation of the NF-kappaB canonical pathway overcomes the resistance of cutaneous T-cell lymphoma to apoptosis.

21 January 2018

1 reference

Inhibition of IkappaB kinase subunit 2 in cutaneous T-cell lymphoma down-regulates nuclear factor-kappaB constitutive activation, induces cell death, and potentiates the apoptotic response to antineoplastic chemotherapeutic agents

21 January 2018

1 reference

Bortezomib induces nuclear translocation of IκBα resulting in gene-specific suppression of NF-κB--dependent transcription and induction of apoptosis in CTCL.

21 January 2018

1 reference

Constitutive activation of a slowly migrating isoform of Stat3 in mycosis fungoides: tyrphostin AG490 inhibits Stat3 activation and growth of mycosis fungoides tumor cell lines

21 January 2018

1 reference

In vivo activation of STAT3 in cutaneous T-cell lymphoma. Evidence for an antiapoptotic function of STAT3.

21 January 2018

1 reference

STAT3 induces transcription of the DNA methyltransferase 1 gene (DNMT1) in malignant T lymphocytes

21 January 2018

1 reference

STAT3 knockdown by siRNA induces apoptosis in human cutaneous T-cell lymphoma line Hut78 via downregulation of Bcl-xL.

21 January 2018

1 reference

Curcumin selectively induces apoptosis in cutaneous T-cell lymphoma cell lines and patients' PBMCs: potential role for STAT-3 and NF-kappaB signaling

21 January 2018

1 reference

Differential effects of interleukin-2 and interleukin-15 versus interleukin-21 on CD4+ cutaneous T-cell lymphoma cells

21 January 2018

1 reference

Molecular cytogenetic characterization of Sézary syndrome

21 January 2018

1 reference

Low FAS/CD95 expression by CTCL correlates with reduced sensitivity to apoptosis that can be restored by FAS upregulation

21 January 2018

1 reference

Reduction of Fas/CD95 promoter methylation, upregulation of Fas protein, and enhancement of sensitivity to apoptosis in cutaneous T-cell lymphoma

21 January 2018

1 reference

Downregulation of Fas gene expression in Sézary syndrome is associated with promoter hypermethylation

21 January 2018

1 reference

Infrequent Fas mutations but no Bax or p53 mutations in early mycosis fungoides: a possible mechanism for the accumulation of malignant T lymphocytes in the skin

21 January 2018

1 reference

Epigenetic profiling of cutaneous T-cell lymphoma: promoter hypermethylation of multiple tumor suppressor genes including BCL7a, PTPRG, and p73

21 January 2018

1 reference

Frequent abnormalities of the p15 and p16 genes in mycosis fungoides and sezary syndrome

21 January 2018

1 reference

CDKN2A-CDKN2B deletion defines an aggressive subset of cutaneous T-cell lymphoma.

21 January 2018

1 reference

Heterogeneous abnormalities of CCND1 and RB1 in primary cutaneous T-Cell lymphomas suggesting impaired cell cycle control in disease pathogenesis.

21 January 2018

1 reference

Identification of tyrosine kinase, HCK, and tumor suppressor, BIN1, as potential mediators of AHI-1 oncogene in primary and transformed CTCL cells

21 January 2018

1 reference

High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascade.

21 January 2018

1 reference

Ectopic expression of B-lymphoid kinase in cutaneous T-cell lymphoma

21 January 2018

1 reference

Long-term outcomes of patients with advanced-stage cutaneous T-cell lymphoma and large cell transformation

21 January 2018

1 reference

Molecular analysis of T-cell receptor beta genes in cutaneous T-cell lymphoma reveals Jbeta1 bias.

21 January 2018

1 reference

T-cell receptor gamma gene rearrangement by multiplex polymerase chain reaction/heteroduplex analysis in patients with cutaneous T-cell lymphoma (mycosis fungoides/Sézary syndrome) and benign inflammatory disease: correlation with clinical, histolog

21 January 2018

1 reference

Cutaneous T-cell lymphoid dyscrasia: a unifying term for idiopathic chronic dermatoses with persistent T-cell clones

21 January 2018

1 reference

Clonal populations of T cells in normal elderly humans: the T cell equivalent to "benign monoclonal gammapathy".

21 January 2018

1 reference

Clonal T-cell populations and increased risk for cytotoxic T-cell lymphomas in B-CLL patients: clinicopathologic observations and molecular analysis

21 January 2018

1 reference

PCR-heteroduplex analysis of T-cell receptor gamma gene rearrangement in paraffin-embedded skin biopsies

21 January 2018

1 reference

T-cell clonality analysis in biopsy specimens from two different skin sites shows high specificity in the diagnosis of patients with suggested mycosis fungoides

21 January 2018

1 reference

Monoclonal T-cell dyscrasia of undetermined significance associated with recalcitrant erythroderma.

21 January 2018

1 reference

Clinicopathological spectrum of mycosis fungoides

21 January 2018

1 reference

Defining early mycosis fungoides.

21 January 2018

1 reference

Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas

21 January 2018

1 reference

Absence of CD26 expression is a useful marker for diagnosis of T-cell lymphoma in peripheral blood

21 January 2018

1 reference

CD158k/KIR3DL2 is a new phenotypic marker of Sezary cells: relevance for the diagnosis and follow-up of Sezary syndrome.

21 January 2018

1 reference

The diagnosis of Sézary syndrome on peripheral blood by flow cytometry requires the use of multiple markers.

21 January 2018

1 reference

Flow cytometric assessment of TCR-Vbeta expression in the evaluation of peripheral blood involvement by T-cell lymphoproliferative disorders: a comparison with conventional T-cell immunophenotyping and molecular genetic techniques

21 January 2018

1 reference

High-scatter T cells: a reliable biomarker for malignant T cells in cutaneous T-cell lymphoma.

21 January 2018

1 reference

Cutaneous T-cell lymphoma: 2011 update on diagnosis, risk-stratification, and management

21 January 2018

1 reference

Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment

21 January 2018

1 reference

Histologic assessment of lymph nodes in mycosis fungoides/Sézary syndrome (cutaneous T-cell lymphoma): clinical correlations and prognostic import of a new classification system

21 January 2018

1 reference

Molecular staging of lymph nodes from 60 patients with mycosis fungoides and Sézary syndrome: correlation with histopathology and outcome suggests prognostic relevance in mycosis fungoides.

21 January 2018

1 reference

Early TCR-beta and TCR-gamma PCR detection of T-cell clonality indicates minimal tumor disease in lymph nodes of cutaneous T-cell lymphoma: diagnostic and prognostic implications.

21 January 2018

1 reference

Clinical features associated with transformation of cerebriform T-cell lymphoma to a large cell process.

21 January 2018

1 reference

Prognostic factor analysis in mycosis fungoides/Sézary syndrome

21 January 2018

1 reference

Transcriptional profiles predict disease outcome in patients with cutaneous T-cell lymphoma

21 January 2018

1 reference

Identification of key regions and genes important in the pathogenesis of sezary syndrome by combining genomic and expression microarrays

21 January 2018

1 reference

A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides

21 January 2018

1 reference

EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome.

21 January 2018

1 reference

Current and emerging treatment strategies for cutaneous T-cell lymphoma

21 January 2018

1 reference

How I treat mycosis fungoides and Sézary syndrome

21 January 2018

1 reference

Joint British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous T-cell lymphomas.

21 January 2018

1 reference

Topical and systemic retinoid therapy for cutaneous T-cell lymphoma

21 January 2018

1 reference

Retinoids: therapeutic applications and mechanisms of action in cutaneous T-cell lymphoma

21 January 2018

1 reference

Bexarotene activates the p53/p73 pathway in human cutaneous T-cell lymphoma

21 January 2018

1 reference

Bexarotene therapy for mycosis fungoides and Sézary syndrome.

21 January 2018

1 reference

Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinion

21 January 2018

1 reference

The optimal use of bexarotene in cutaneous T-cell lymphoma

21 January 2018

1 reference

U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma

21 January 2018

1 reference

Management of refractory early-stage cutaneous T-cell lymphoma (mycosis fungoides) with a combination of oral bexarotene and psoralen plus ultraviolet bath therapy

21 January 2018

1 reference

Cytotoxicity mediated by histone deacetylase inhibitors in cancer cells: mechanisms and potential clinical implications

21 January 2018

1 reference

Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1

21 January 2018

1 reference

Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation

21 January 2018

1 reference

P21-dependent g(1)arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228

21 January 2018

1 reference

Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action

21 January 2018

1 reference

Activity of deacetylase inhibitor panobinostat (LBH589) in cutaneous T-cell lymphoma models: Defining molecular mechanisms of resistance

21 January 2018

1 reference

Acetylation is indispensable for p53 activation

21 January 2018

1 reference

Acetylation of p53 at lysine 373/382 by the histone deacetylase inhibitor depsipeptide induces expression of p21(Waf1/Cip1).

21 January 2018

1 reference

Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-kappaB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation

21 January 2018

1 reference

Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma

21 January 2018

1 reference

Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells

21 January 2018

1 reference

Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity

21 January 2018

1 reference

Actions of a histone deacetylase inhibitor NSC3852 (5-nitroso-8-quinolinol) link reactive oxygen species to cell differentiation and apoptosis in MCF-7 human mammary tumor cells

21 January 2018

1 reference

Induction of MAGE-3 expression in lung and esophageal cancer cells

21 January 2018

1 reference

The histone deacetylase inhibitors vorinostat and romidepsin downmodulate IL-10 expression in cutaneous T-cell lymphoma cells.

21 January 2018

1 reference

Expression of histone deacetylases in lymphoma: implication for the development of selective inhibitors.

21 January 2018

1 reference

Clinical studies of histone deacetylase inhibitors.

21 January 2018

1 reference

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

21 January 2018

1 reference

Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma

21 January 2018

1 reference

Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphoma

21 January 2018

1 reference

Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma

21 January 2018

1 reference

Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma

21 January 2018

1 reference

Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma

21 January 2018

1 reference

Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma

21 January 2018

1 reference

Increased MDR1 expression in normal and malignant peripheral blood mononuclear cells obtained from patients receiving depsipeptide (FR901228, FK228, NSC630176).

21 January 2018

1 reference

HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy

21 January 2018

1 reference

MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: rationale to combine romidepsin with an MEK inhibitor

21 January 2018

1 reference

Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma

21 January 2018

1 reference

Long-term follow-up in 51 patients with mycosis fungoides and Sézary syndrome treated by interferon-alfa

21 January 2018

1 reference

Interferon alfa-2a combined with phototherapy in the treatment of cutaneous T-cell lymphoma.

21 January 2018

1 reference

Combination treatment with extracorporeal photopheresis, interferon alfa and interleukin-2 in a patient with the Sézary syndrome

21 January 2018

1 reference

Photochemotherapy alone or combined with interferon alpha-2a in the treatment of cutaneous T-cell lymphoma.

21 January 2018

1 reference

Extracorporeal photopheresis: a focus on apoptosis and cytokines

21 January 2018

1 reference

Rapid generation of maturationally synchronized human dendritic cells: contribution to the clinical efficacy of extracorporeal photochemotherapy

21 January 2018

1 reference

Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results

21 January 2018

1 reference

Extracorporeal photochemoimmunotherapy in cutaneous T-cell lymphoma

21 January 2018

1 reference

The treatment of cutaneous T-cell lymphoma with photopheresis

21 January 2018

1 reference

Extracorporeal photopheresis for the treatment of erythrodermic cutaneous T-cell lymphoma: a single center clinical experience with long-term follow-up data and a brief overview of the literature

21 January 2018

1 reference

Guidelines on the use of extracorporeal photopheresis

21 January 2018

1 reference

Treatment of cutaneous T-cell lymphoma with extracorporeal photopheresis monotherapy and in combination with recombinant interferon alfa: a 10-year experience at a single institution

21 January 2018

1 reference

Experience with total skin electron beam therapy in combination with extracorporeal photopheresis in the management of patients with erythrodermic (T4) mycosis fungoides

21 January 2018

1 reference

Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome

21 January 2018

1 reference

Low-dose intermittent alemtuzumab in the treatment of Sézary syndrome: clinical and immunologic findings in 14 patients.

21 January 2018

1 reference

Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab*.

21 January 2018

1 reference

A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas

21 January 2018

1 reference

Successful treatment of chemotherapy-refractory Sézary syndrome with alemtuzumab (Campath-1H).

21 January 2018

1 reference

Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma.

21 January 2018

1 reference

Efficacy and tolerability of currently available therapies for the mycosis fungoides and Sezary syndrome variants of cutaneous T-cell lymphoma

21 January 2018

1 reference

Low-dose methotrexate to treat erythrodermic cutaneous T-cell lymphoma: results in twenty-nine patients

21 January 2018

1 reference

Low-dose methotrexate to treat mycosis fungoides: a retrospective study in 69 patients

21 January 2018

1 reference

Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients

21 January 2018

1 reference

Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients

21 January 2018

1 reference

Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma.

21 January 2018

1 reference

Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome.

21 January 2018

1 reference

Prospective multicenter study of pegylated liposomal doxorubicin treatment in patients with advanced or refractory mycosis fungoides or Sézary syndrome

21 January 2018

1 reference

Deoxycoformycin in the treatment of mature T-cell leukaemias

21 January 2018

1 reference

Pentostatin in T-cell malignancies--a phase II trial of the EORTC. Leukemia Cooperative Group

21 January 2018

1 reference

Phase II study of pentostatin in advanced T-cell lymphoid malignancies: update of an M.D. Anderson Cancer Center series

21 January 2018

1 reference

Gemcitabine treatment in cutaneous T-cell lymphoma: a multicentre study of 23 cases

21 January 2018

1 reference

Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma

21 January 2018

1 reference

Single agent and combination studies of pralatrexate and molecular correlates of sensitivity

21 January 2018

1 reference

Pralatrexate: basic understanding and clinical development

21 January 2018

1 reference

Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study

21 January 2018

1 reference

Pralatrexate, a new hope for aggressive T-cell lymphomas?

21 January 2018

1 reference

Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma

21 January 2018

1 reference

A meta-analysis of patients receiving allogeneic or autologous hematopoietic stem cell transplant in mycosis fungoides and Sézary syndrome.

21 January 2018

1 reference

Haematopoietic stem cell transplantation for patients with primary cutaneous T-cell lymphoma

21 January 2018

1 reference

Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.

21 January 2018

1 reference

Allogeneic stem cell transplantation for advanced primary cutaneous T-cell lymphoma: a systematic review

21 January 2018

1 reference

Cutaneous T-cell lymphoma: malignant proliferation of T-regulatory cells

21 January 2018

1 reference

Detection of a Peripheral Blood T Cell Clone is an Independent Prognostic Marker in Mycosis Fungoides

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/AJH.23756

0 references

PubMed publication ID

25042790

1 reference